Scholarlink

Background <p>Hepatocellular carcinoma (HCC) remains a significant worldwide health burden, accounting for a substantial proportion of cancer-associated morbidity and mortality. Therapeutic strategies for HCC have advanced considerably over the past decade, particularly with the introduction of immunotherapy. Immune-based treatments have transformed the management of this malignancy.</p> Methods <p>A retrospective case series of four HCC patients who had histologically or radiologically confirmed HCC and received adjuvant treatment within 12&#xa0;weeks after completion of curative therapy.</p> Results <p>Four patients were treated with anti-PD-L1, two of them received a full course for 18&#xa0;cycles with tolerated side-effects and no recurrence, one experienced recurrence after 12&#xa0;cycles, and the last case received only 3&#xa0;months of treatment after local ablation with very early recurrence on the first follow-up.</p> Conclusion <p>Adjuvant ICIs may reduce recurrence in select high-risk HCC patients, though long-term benefits remain uncertain. Safety and tolerability are key considerations, especially in patients with underlying liver disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adjuvant anti-PD-L1 therapy for hepatocellular carcinoma following curative treatment: case series

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月7日

查看全文
  • Noura Gamal,
  • Rasha Abdelhafiz Aly,
  • Alzhraa Alkhatib,
  • Asmaa Gomaa,
  • Naglaa Allam,
  • Imam Waked

摘要

Background

Hepatocellular carcinoma (HCC) remains a significant worldwide health burden, accounting for a substantial proportion of cancer-associated morbidity and mortality. Therapeutic strategies for HCC have advanced considerably over the past decade, particularly with the introduction of immunotherapy. Immune-based treatments have transformed the management of this malignancy.

Methods

A retrospective case series of four HCC patients who had histologically or radiologically confirmed HCC and received adjuvant treatment within 12 weeks after completion of curative therapy.

Results

Four patients were treated with anti-PD-L1, two of them received a full course for 18 cycles with tolerated side-effects and no recurrence, one experienced recurrence after 12 cycles, and the last case received only 3 months of treatment after local ablation with very early recurrence on the first follow-up.

Conclusion

Adjuvant ICIs may reduce recurrence in select high-risk HCC patients, though long-term benefits remain uncertain. Safety and tolerability are key considerations, especially in patients with underlying liver disease.